featured
AAN 2021: COMET Findings Suggest Avalglucosidase Alfa Could Become New Standard for Late-Onset Pompe Disease
Compared with current standard treatment, it offered at least as good functional outcomes with a better safety profile
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.